Diabetologia

, Volume 55, Issue 12, pp 3245–3251

Effect of a common variant of the PCSK2 gene on reduced insulin secretion

Authors

  • A. Jonsson
    • Department of Clinical Sciences, Diabetes and EndocrinologyLund University, CRC, Skåne University Hospital
  • B. Isomaa
    • Folkhalsan Research Centre
    • Department of Social Services and Health Care
  • T. Tuomi
    • Folkhalsan Research Centre
    • Department of MedicineHelsinki University Central Hospital
  • J. G. Eriksson
    • Folkhalsan Research Centre
    • National Public Health Institute
    • Department of General Practice and Primary HealthcareUniversity of Helsinki
    • Vasa Central Hospital
    • Unit of General PracticeHelsinki University Central Hospital
  • L. Groop
    • Department of Clinical Sciences, Diabetes and EndocrinologyLund University, CRC, Skåne University Hospital
    • Finnish Institute of Molecular Medicine (FIMM)Helsinki University
    • Department of Clinical Sciences, Diabetes and EndocrinologyLund University, CRC, Skåne University Hospital
Article

DOI: 10.1007/s00125-012-2728-5

Cite this article as:
Jonsson, A., Isomaa, B., Tuomi, T. et al. Diabetologia (2012) 55: 3245. doi:10.1007/s00125-012-2728-5

Abstract

Aim/hypothesis

Individuals at risk of developing type 2 diabetes show a progressive decline in insulin secretion and increased insulin resistance over time. However, inability of the beta cells to compensate for the increased insulin resistance represents a key defect leading to overt type 2 diabetes. The aims of the present study were to replicate the association between genetic variants of the PCSK2 gene and insulin secretion, and to explore the effect on risk of type 2 diabetes.

Methods

Replication of PCSK2 variants against insulin secretion included 7,682 non-diabetic Scandinavian individuals. Insulin secretion was measured as the corrected insulin response or disposition index, i.e. insulin secretion adjusted for the degree of insulin resistance. Risk of type 2 diabetes was studied in 28,287 Scandinavian individuals.

Results

The C-allele of PCSK2 rs2208203 was associated with reduced insulin secretion measured as the corrected insulin response (n = 8,151; β = −0.112, p = 1.3 × 10−6) as well as disposition index (n = 8,078, β = −0.128, p = 1.6 × 10−7). The variant was also associated with lower fasting glucagon levels (β = −0.084, p = 0.005) in non-diabetic individuals with a fasting plasma glucose of over 5.5 mmol/l. In human pancreatic islets, PCSK2 expression correlated negatively with HbA1c (n = 133, r = −0.196, p = 0.038), and showed a tendency to be lower in hyperglycaemic (HbA1c ≥6.0% or type 2 diabetes; n = 47, p = 0.13) than normoglycaemic (HbA1c >6.0%; n = 66) donors. The presence of the PCSK2 rs2208203 risk allele did not influence gene expression, nor did it show an apparent risk in terms of type 2 diabetes.

Conclusions/interpretation

A variant of the PCSK2 gene was associated with reduced glucose-stimulated insulin secretion, but also with lower glucagon levels, which could potentially counteract the effects of decreased insulin secretion on the risk of type 2 diabetes.

Keywords

GeneticsInsulin secretionType 2 diabetes

Abbreviations

BPS

Botnia Prospective Study

CIR

Corrected insulin response

DGI

Diabetes Genetics Initiative

DI

Disposition index

GWAS

Genome-wide association study

HBCS

Helsinki Birth Cohort Study

ISI

Insulin sensitivity index

MCC

Malmö Case–Control

MPP

Malmö Preventive Project

PC2

Proprotein convertase subtilisin/kexin type 2

PPP-Botnia

Prevalence, Prediction and Prevention of Diabetes Botnia study

SNP

Single nucleotide polymorphism

Introduction

Individuals at risk of developing type 2 diabetes show a progressive decline in insulin secretion and increased insulin resistance over time. However, an inability of the beta cells to compensate for the degree of insulin resistance represents a key defect leading to overt type 2 diabetes. Several genome-wide association studies (GWASs) have identified a number of genetic loci resulting in impaired islet function and an increased risk of type 2 diabetes [15].

We previously identified an association between a common variant of the MTNR1B gene and reduced insulin secretion in the Diabetes Genetics Initiative (DGI) GWAS [6]. In addition, variants in the proprotein convertase subtilisin/kexin type 2 gene (PCSK2) were associated with reduced insulin secretion in the analysis of early insulin secretion in the DGI study, which included 999 non-diabetic individuals with information on glucose and insulin concentrations during an OGTT. The protein coded by this gene, PC2, is a proinsulin-processing enzyme that plays a key role in regulating insulin and glucagon biosynthesis. PCSK2 is expressed in the brain and the pancreatic islets. Variants of the PCSK1 and PCSK2 genes have previously been linked to type 2 diabetes and obesity [711]. The aims of the current study were to study the association between genetic variants of the PCSK2 gene and insulin secretion, and to explore the effect on risk of type 2 diabetes.

Methods

Study populations

The DGI consisted of 1,464 individuals with type 2 diabetes and 1,467 euglycaemic controls from Finland and Sweden [2]; 999 of the control participants had data available on glucose and insulin levels at fasting, 30, and 120 min during OGTTs.

The Prevalence, Prediction and Prevention of Diabetes Botnia (PPP-Botnia) study is a population-based study from the Botnia region of western Finland. A total of 4,650 non-diabetic participants (n = 4,007 who did not overlap with the DGI; fasting plasma glucose <7.0 mmol/l and 2 h plasma glucose <11.1 mmol/l) were included in the current study [12].

The Botnia Prospective Study (BPS) started in 1990 on the west coast of Finland with the aim of identifying genes increasing susceptibility to type 2 diabetes in members of families with type 2 diabetes [13]. The prospective arm of the study included 2,770 non-diabetic family members and/or their spouses (1,263 men and 1,507 women, mean age 45 years), 138 of whom developed type 2 diabetes during a 7.7-year [14] follow-up period [15, 16]. All participants were given information about exercise and a healthy diet, and were retested with an OGTT at 2–3-year intervals. Overall, 1,987 non-diabetic individuals with available longitudinal measurements of insulin and glucose concentrations during OGTTs were included in the analyses for insulin secretion, while 2,770 individuals were included in the analyses for type 2 diabetes.

The Helsinki Birth Cohort Study (HBCS) included 2,003 participants (928 men and 1,075 women) aged 56–70 years, who had been born as singletons between 1934 and 1944. All participants underwent an OGTT [17]. The insulin secretion analyses included 1,688 individuals without diabetes.

The Malmö Case–Control (MCC) study consisted of 3,436 participants with diabetes from the local Scania Diabetes Registry [18] and 3,427 non-diabetic controls from the population-based Malmö Diet and Cancer study [19] in southern Sweden. All diabetic participants were of Scandinavian origin and had an age at onset of diabetes of over 35 years, a C-peptide level of ≥0.3 nmol/l and no glutamic acid decarboxylase (GAD) antibodies. Controls were also of Scandinavian origin and had a fasting blood glucose below 5.5 mmol/l and an HbA1c of less than 6.0%.

The Malmö Preventive Project (MPP) is a large population-based prospective study from the city of Malmö, Sweden, consisting of 33,346 Swedish individuals who participated in a health screening over the period 1974–1992 [20]. All participants underwent a physical examination, and each had blood drawn for measurements of fasting blood glucose and lipid concentration. A total of 16,651 participants, 3,089 of whom developed type 2 diabetes during a median 28.6-year follow-up period, were included in the current analyses [14]. A diagnosis of diabetes was confirmed from patient records or based on a fasting plasma glucose concentration greater than 7.0 mmol/l.

Human pancreatic islets from 128 human cadaver donors were provided by the Nordic network for clinical islet transplantation. The experimental protocol for isolation of the islets was approved by the ethics committee of Uppsala University and performed in accordance with local institutional and Swedish national regulations.

Measurements

Blood samples were drawn at −10, 0, 30, 60 and 120 min during the OGTT both at baseline and at follow-up for the BPS cohort, and at 0, 30 and 120 min for PPP-Botnia. Proinsulin was measured in pmol/l using human proinsulin RIA (Linco Research, St Charles, MO, USA), serum glucagon in pg/ml using radioimmunoassay (Millipore, St Charles, MO, USA). The insulin sensitivity index (ISI) from the OGTT was calculated as \( {{{{1}0,000}} \left/ {\surd } \right.}\left( {{\mathrm{fasting}}\;{\mathrm{plasma}}\;{\mathrm{glucose}} \times {\mathrm{fasting}}\;{\mathrm{plasma}}\;{\mathrm{insulin}} \times {\mathrm{mean}}\;{\mathrm{OGT}}{{\mathrm{T}}_{\mathrm{glucose}}} \times {\mathrm{mean}}\;{\mathrm{OGT}}{{\mathrm{T}}_{\mathrm{insulin}}}} \right) \) [21]. Beta cell function was assessed as the corrected insulin response (CIR) during the OGTT \( \left( {{\mathrm{CIR}} = {{{{1}00 \times {\mathrm{insulin}}\;{\mathrm{at}}\;{3}0\;{\min }}} \left/ {{\left[ {{\mathrm{glucose}}\;{\mathrm{at}}\;{3}0 {\min } \times \left( {{\mathrm{glucose}}\;{3}0\;{\min } - {3}.{89}} \right)} \right]}} \right.}} \right) \) [22] or as the disposition index (DI), i.e. insulin secretion adjusted for insulin sensitivity \( \left( {{\mathrm{DI}} = {\mathrm{CIR}} \times {\mathrm{ISI}}} \right) \).

Genotyping

Genotyping was performed using an Affymetrix 500 K chip (Affymetrix, Santa Clara, CA, USA) for the DGI cohort, with matrix-assisted laser desorption–ionisation time-of-flight mass spectrometry on a MassARRAY platform (Sequenom, San Diego, CA, USA) for the PPP-Botnia cohort, and by an allelic discrimination method with a TaqMan assay on an ABI 7900 platform (Applied Biosystems, Foster City, CA, USA) for the remaining cohorts. We obtained an average genotyping success rate of 95.9%, and the average concordance rate, based on 2,814 (8.5%) duplicate comparisons, was 99.5%. Hardy–Weinberg equilibrium was fulfilled in all populations studied (p > 0.05).

Glucose-stimulated insulin secretion and gene expression in human pancreatic islets

Total RNA was isolated using an AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). The quality and concentration of the RNA were measured using an Agilent 2100 bioanalyser (Agilent, Santa Clara, CA, USA) and Nanodrop ND-1000 equipment (Nanodrop, Wilmington, DE, USA), respectively. Glucose-stimulated insulin secretion was performed in high (16.7 mmol/l) and low (1.0 mmol/l) concentrations of glucose in the medium as previously described [23]. Glucose-stimulated insulin secretion was expressed as the fold change in insulin release from the islets by comparing release at 16.7 mmol/l with release using the 1.0 mmol/l glucose medium. The microarrays were performed following the Affymetrix standard protocol as previously described [23].

Statistical analysis

Variables in Table 1 are presented as mean ± SD, and if not normally distributed as median (interquartile range). The risk of developing type 2 diabetes is expressed as the OR using logistic regression analyses adjusted for age, sex and BMI. Genotype–phenotype correlations were studied using linear regression analyses adjusted for age, sex and BMI. The BPS was analysed using corrected residuals in PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/) [24] with the family-based association tests for quantitative traits (QFAM-total) method with adaptive permutation to correct for family structure. Non-normally distributed variables (CIR, DI, ISI and proinsulin and glucagon levels) were logarithmically (natural log) transformed for analysis. For analysis of data from human pancreatic islets, a non-parametric t test was used to assess the association between genotype and phenotype (expression and insulin secretion), and Spearman’s rank correlation test was used for the association between PCSK2 mRNA and HbA1c levels. All statistical analyses were performed using IBM SPSS Statistics version 19.0 (IBM, Armonk, NY, USA) and PLINK version 1.07. Meta-analyses were performed with the Metan analytical tool package implemented in STATA SE v. 10.1 (StataCorp, College Station, TX, USA) using fixed-effect models with the inverse variance method. Two-sided p values of less than 0.05 were considered statistically significant.
Table 1

Characteristics of the study participants

 

DGI

PPP-Botnia Study

BPS

HBCS

MCC

MPP

Cases

Controls

Number (m/f)

999 (479/520)

4,650 (2,157/2,493)

2,770 (1,263/1,507)

2,003 (928/1075)

3,436 (1,969/1,467)

3,427 (1,265/2,162)

16,651 (10,762/5,889)

Age (years)

58.7 ± 10.1

48.0 ± 15.2

44.9 ± 14.2

61.5 ± 2.9

53.8 ± 13.0

57.4 ± 6.1

44.9 ± 7.4

BMI (kg/m2)

26.7 ± 3.8

26.2 ± 4.3

25.6 ± 4.1

27.6 ± 4.6

29.7 ± 5.6

25.0 ± 3.6

24.3 ± 3.4

Fasting plasma glucose (mmol/l)

5.31 ± 0.52

5.26 ± 0.56

5.52 ± 0.58

5.49 ± 0.56

12.02 ± 4.29

4.78 ± 0.36

4.92 ± 0.76

ISI

129.6 (96.4)

147.4 (112.0)

147.7 (112.4)

87.8 (71.1)

CIR

149.7 (172.6)

151.0 (153.5)

112.8 (124.5)

138.4 (146.4)

DI

18,640 (18,240)

21,450 (23,450)

15,780 (19,120)

11,680 (12,330)

Type 2 diabetes converters

138

311

3,089

Follow-up time (years)

6.7 (5.0)

60.9 (4.3)

28.6 (6.1)

PCSK2 rs2208203 risk allele frequency

0.063

0.068

0.068

0.106

0.077

0.069

0.065

Data are means ± SD or median (interquartile range)

Baseline characteristics are shown for the BPS and MPP. Fasting plasma glucose, ISI, CIR and DI are presented for non-diabetic individuals

Results

Effect of genetic variants in the PCSK2 gene on insulin secretion

In the DGI GWAS [2, 6], we identified a PCSK2 locus as being consistently associated with insulin secretion in both non-diabetic and diet-treated diabetic individuals (p < 0.01) (see electronic supplementary material [ESM] Table 1) and selected five single nucleotide polymorphisms (SNPs) for follow-up validation in the non-diabetic participants from the PPP-Botnia study (ESM Table 2). We found two SNPs, rs2208203 and rs6034804 (Dʹ = 0.85, r2 = 0.62), in the PCSK2 gene that were associated (p < 1 × 10−4) with insulin secretion in this replication study of approximately 2,800 participants and remained significant after Bonferroni correction.

Next, we examined whether the association between our strongest replication signal of PCSK2 rs2208203 and reduced insulin secretion could be replicated in additional cohorts (Tables 1 and 2). In line with the effect of the variant of PCSK2 in the DGI and PPP-Botnia study, C-allele carriers of rs2208203 showed decreased insulin secretion in the HBCS study (CIR β = −0.103 [SE 0.043], p = 0.018; DI β = −0.135 [SE 0.045], p = 0.0025). The meta-analysis of all studies, totalling more than 8,100 individuals, showed that the C-allele was associated with an 11% reduction in CIR (p = 1.3 × 10−6) and a 13% reduction in DI (p = 1.6 × 10−7) (Fig. 1). Furthermore, we observed that carriers of the risk C-allele had reduced fasting glucagon levels (β = −0.084 [SE 0.030], p = 0.0048) in the hyperglycaemic (fasting plasma glucose >5.5 mmol/l) participants from the PPP-Botnia study (ESM Table 3). The SNP rs2208203 did not seem to influence proinsulin concentrations, nor did the variant have a significant effect on insulin sensitivity or BMI.
Table 2

Effects of PCSK2 rs2208203 on insulin secretion and sensitivity in non-diabetic individuals from the populations studied

 

n

β

SE

p value

DGI study

  Insulin secretion (CIR)

999

−0.191

0.099

0.060

  DI

999

−0.260

0.084

0.0023

  ISI

999

0.006

0.098

0.95

PPP-Botnia study

  Insulin secretion (CIR)

3,711

−0.128

0.035

2.2 × 10−4

  DI

3,641

−0.108

0.037

0.0032

  ISI

3,655

0.014

0.023

0.55

BPS

  Baseline

    Insulin secretion (CIR)

1,886

−0.071

0.049

0.19

    DI

1,886

−0.096

0.051

0.10

    ISI

1,886

−0.025

0.032

0.49

  Follow-up

    Insulin secretion (CIR)

1,886

0.011

0.050

0.84

    DI

1,886

−0.025

0.055

0.69

    ISI

1,886

−0.037

0.035

0.35

HBCS

  Insulin secretion (CIR)

1,559

−0.103

0.043

0.018

    DI

1,556

−0.135

0.045

0.0025

    ISI

1,558

−0.031

0.031

0.32

Meta-analyses

    Insulin secretion (CIR)

8,151

−0.112

0.023

1.3 × 10−6

    DI

8,078

−0.125

0.024

1.6 × 10−7

    ISI

8,094

−0.007

0.016

0.65

β and SE obtained from linear regression analysis adjusted for age, sex and BMI. The effect size is presented for each C-allele (additive model). Meta-analyses included the DGI study, PPP-Botnia study (participants not overlapping with the DGI study), HBCS and BPS at baseline

https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2728-5/MediaObjects/125_2012_2728_Fig1_HTML.gif
Fig. 1

Meta-analyses of PCSK2 rs2208203 for insulin secretion and insulin sensitivity. (a) CIR; the C-allele was associated with reduced insulin secretion. Meta-analysis: β = −0.112 (SE 0.023), p = 1.3 × 10−6. (b) DI, i.e. insulin secretion adjusted for degree of insulin sensitivity; the C-allele was associated with a reduced DI. Meta-analysis: β = −0.125 (SE 0.024), p = 1.6 × 10−7. (c) Insulin sensitivity; the C-allele did not show any significant effect on insulin sensitivity. Meta-analysis: β = −0.007 (SE 0.016), p = 0.65

Effect of genetic variations in the PCSK2 gene on risk of type 2 diabetes

Having observed an effect of the C-allele of rs2208203 in PCSK2 in terms of reducing insulin secretion, we next asked whether this impairment of insulin secretion was translated into an increased risk of type 2 diabetes. In the MCC, the C-allele of rs2208203 was only weakly associated with risk of type 2 diabetes (OR 1.14, 95% CI [0.98, 1.34], p = 0.086). However, we were not able to validate the association of SNP rs2208203 with type 2 diabetes in our large prospective cohorts including 21,424 individuals followed for 27 years, of whom 3,538 developed diabetes (ESM Table 4).

Expression of PCSK2 and glucose-stimulated insulin secretion in human pancreatic islets

We also analysed whether the level of glycaemia and/or the SNP influenced expression of the PCSK2 gene using microarray analysis of human pancreatic islets from 128 donors, 84 of whom also had information on glucose-stimulated insulin secretion. PCSK2 mRNA correlated negatively with HbA1c levels (r = −0.196, p = 0.038, n = 113) (Fig. 2), and gene expression showed a tendency to be lower in hyperglycaemic (HbA1c ≥ 6.0% or type 2 diabetes, n = 47) compared with normoglycaemic (HbA1c < 6.0%, n = 66) donors (p = 0.13). There was no significant correlation between PCSK2 expression and insulin release at high and low glucose concentrations, nor did the rs2208203 variant influence PCSK2 expression or insulin secretion (ESM Table 5).
https://static-content.springer.com/image/art%3A10.1007%2Fs00125-012-2728-5/MediaObjects/125_2012_2728_Fig2_HTML.gif
Fig. 2

Spearman correlation between PCSK2 mRNA and HbA1c in human islets. There was a negative correlation between PCSK2 expression and HbA1c level (r = −0.196, p = 0.038, n = 113). To convert values for HbA1c in % into mmol/mol, subtract 2.15 and multiply by 10.929

Discussion

Here we report that a common variant of the PCSK2 gene is associated with reduced insulin secretion. PC2, the protein encoded by PCSK2, is involved in the regulation of insulin and glucagon biosynthesis and is therefore a plausible candidate gene for the development of type 2 diabetes. Defects in the catalytic activity of prohormone enzymes would lead to abnormal hormone-processing. Although we were not able to measure PC2 activity in human islets, the lower PCSK2 expression observed in hyperglycaemic donors could indicate decreased concentrations of PC2 and in turn lead to decreased production of insulin and glucagon peptides in the islets. We cannot, however, exclude the effects on expression being secondary to a long-term increase in glucose levels as no correlation was seen between PCSK2 expression and insulin secretion in vitro. Notably, the PCSK2 variants were strongly associated with reduced early glucose-stimulated insulin secretion at 30 min during the OGTTs. This is in agreement with studies using MIN6 cells that demonstrate the rapid effects of glucose, occurring after a 20-min lag period and reaching maximum at 60 min, on the regulation of both PC2 and proinsulin biosynthesis [25].

Given that PCSK2 variants affected neither proinsulin nor C-peptide levels, this would suggest primary effects on insulin synthesis. Pcsk2 knockout mice show decreased growth, reduced adiposity and protection from dietary fat-induced body weight gain. In addition, they exhibit fasting hypoglycaemia, reduced blood glucose and reduced circulating glucagon during intraperitoneal glucose tolerance testing. Processing of proglucagon and proinsulin is severely impaired in these mice [26, 27]. Furthermore, supporting the notion of PC2 effects on proglucagon processing, we observed that the PCSK2 variant was associated with lower glucagon levels in hyperglycaemic individuals.

The PCSK2 gene is located on chromosome 20p11.2 and consists of 12 exons with a protein coding region of 257.6 kbp. Variants in the PCSK2 gene have previously been associated with type 2 diabetes in African [9], Japanese [10] and Chinese [11] individuals, but not, to our knowledge, European populations. Here we report an independent signal in intron 2 of PCSK2 in Scandinavian populations that was not correlated with previously reported variants in African (rs2021785), Japanese (microsatellite marker in intron 2) and Chinese (rs2021785) populations. Of note, none of the previously reported variants showed an association with insulin secretion in the DGI [2]. In the present study, the variant rs2208203 was not associated with risk of type 2 diabetes in a total of 21,313 non-diabetic and 6,974 diabetic individuals. One potential reason for the lack of apparent risk of type 2 diabetes could be the concomitant effect of PCSK2 variant on lowering glucagon levels.

In conclusion, a variant the PCSK2 gene (rs2208203) was associated with reduced glucose-stimulated insulin secretion, but also with lower glucagon levels that potentially counteracted the effects of decreased insulin secretion on risk of type 2 diabetes. These findings, together with several earlier observations, support an involvement of the PCSK2 gene in the pathogenesis of type 2 diabetes.

Acknowledgements

Human islets were provided by the Nordic network for clinical islets transplantation courtesy of O. Korsgren, Uppsala, Sweden, and the expression studies were performed by the Human Tissue Laboratory at Lund University Diabetes Centre (LUDC). We thank the patients for their participation and the Botnia Study Group for clinical study of the patients.

Funding

Studies at LUDC, Malmö were supported by grants from the Swedish Research Council, including a Linné grant (No. 349-2008-6589), a strategic research area grant Exodiab (2009-1039), the Heart and Lung Foundation, the Swedish Diabetes Research Society, the European Community's Seventh Framework Programme (grant CEED3, 223211), the Diabetes Programme at the Lund University, the Påhlsson Foundation, the Crafoord Foundation, the Knut and Alice Wallenberg Foundation, Novo Nordisk Foundation and the European Foundation for the Study of Diabetes. The Botnia studies were supported by grants from the Sigrid Juselius Foundation, the Folkhälsan Research Foundation, the Finnish Diabetes Research Society, the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Ollqvist Foundation, Ministry of Education of Finland, the Foundation for Life and Health in Finland, Jakobstad Hospital, the Medical Society of Finland, the Närpes Research Foundation and the Vasa and Närpes Health centres.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

AJ designed the study, researched and interpreted the data and wrote the manuscript. BI, TT and JGE collected and phenotyped the study populations. LG and VL designed and supervised the study, interpreted the data and contributed to discussion. All authors reviewed and approved the final version of the manuscript.

Supplementary material

125_2012_2728_MOESM1_ESM.pdf (70 kb)
ESM Table 1PDF 70.4 kb
125_2012_2728_MOESM2_ESM.pdf (38 kb)
ESM Table 2PDF 37.8 kb
125_2012_2728_MOESM3_ESM.pdf (45 kb)
ESM Table 3PDF 45.4 kb
125_2012_2728_MOESM4_ESM.pdf (9 kb)
ESM Table 4PDF 8.73 kb
125_2012_2728_MOESM5_ESM.pdf (8 kb)
ESM Table 5PDF 8.19 kb

Copyright information

© Springer-Verlag 2012